Xieqiao Yan

Peking University - Key Laboratory of Carcinogenesis and Translational Research

Beijing Cancer Hospital

SCHOLARLY PAPERS

2

DOWNLOADS

52

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study

Number of pages: 27 Posted: 30 Nov 2023
Bin Lian, Juan Li, Lu Si, Zhihong Chi, Lili Mao, Xuan Wang, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Yuping Shen, Qun Guo, Shirui Zheng, Jun Guo and Chuanliang Cui
Beijing Cancer Hospital, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Innovent Biologics, Inc., Innovent Biologics, Inc., Innovent Biologics, Inc., Peking University - Key Laboratory of Carcinogenesis and Translational Research and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 45 (896,170)

Abstract:

Loading...

CTLA-4, IBI310, Combination immunotherapy, Melanoma, Urothelial carcinoma

2.

Efficacy and Safety of Disitamab vedotin (RC48-ADC) in HER2-Negative Locally Advanced or Metastatic Urothelial Carcinoma: Results from a Phase 2 Clinical Study

Number of pages: 45 Posted: 11 Sep 2024
Xieqiao Yan, Juan Li, Huayan Xu, Li Zhou, Siming Li, Xiaowen Wu, Bixia Tang, Zhihong Chi, Chuanliang Cui, Lu Si, Lili Mao, Bin Lian, Xuan Wang, Rong Duan, Caili Li, Jianmin Fang, Jun Guo, Xinan Sheng and Sneak Peek Administrator
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, RemeGen, Ltd., Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research and Independent
Downloads 7 (1,307,098)

Abstract:

Loading...

Urothelial Carcinoma, Antibody Drug Conjugate, HER2-Negative, Disitamab Vedotin